Still happy to risk $1bn on p=0.05?
This article was originally published in Scrip
How would all of you out there in Pharmaland feel if a paper published in a reputable science journal suggested that clinical trials were a bogus way of gathering information to decide whether to progress a given compound towards the clinic?
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.